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Available online 17 November 2016Sustained anabolic-androgenic steroid (AAS) use has adverse behavioral consequences, including aggression, vi-
olence and impulsivity. Candidatemechanisms include disruptions of brain networkswith high concentrations of
androgen receptors and critically involved in emotional and cognitive regulation. Here, we tested the effects of
AAS on resting-state functional brain connectivity in the largest sample of AAS-users to date. We collected rest-
ing-state functional magnetic resonance imaging (fMRI) data from 151 males engaged in heavy resistance
strength training. 50 users tested positive for AAS based on the testosterone to epitestosterone (T/E) ratio and
doping substances in urine. 16 previous users and 59 controls tested negative. We estimated brain network
nodes and their time-series using ICA and dual regression and deﬁned connectivity matrices as the between-
node partial correlations. In linewith the emotional and behavioral consequences of AAS, current users exhibited
reduced functional connectivity between key nodes involved in emotional and cognitive regulation, in particular
reduced connectivity between the amygdala and default-mode network (DMN) and between the dorsal atten-
tion network (DAN) and a frontal node encompassing the superior and inferior frontal gyri (SFG/IFG) and the an-
terior cingulate cortex (ACC), with further reductions as a function of dependency, lifetime exposure, and cycle
state (on/off).
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
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Dependency1. Introduction
Anabolic androgenic steroids (AAS) comprise a large category of
synthetic derivatives of the male sex hormone testosterone widely
used for cosmetic or ergogenic purposes (Ip et al., 2011; Kanayama et
al., 2009b; Kanayama et al., 2001). In addition to the performance en-
hancing and tissue building properties, AAS is associated with a wide
range of symptoms, including aggression, violence and impulsive be-
haviors (Pagonis et al., 2006b; Trenton and Currier, 2005). While posi-
tive effects of AAS on mood, such as transient euphoria and
hypomania, have been reported early in the course of AAS use (Thiblin
and Petersson, 2005), anxiety, impulsivity, marked irritability and ag-
gression is commonly manifested after long-term use (Hall and
Chapman, 2005; Pagonis et al., 2006b; Pope et al., 2000; Trenton and
Currier, 2005). Moreover, emerging evidence suggests that prolonged
AAS use is associated with cognitive impairments including self-report-
ed memory (Heffernan et al., 2015a; Su et al., 1993), working memory
and visuospatial abilities (Kanayama et al., 2012; Kaufman et al., 2015).Box 4956, Nydalen, 0424 Oslo,
tlye).
. This is an open access article underWhereas the exact mechanisms of the adverse consequences of AAS
use are unclear, they are likely partly reﬂecting disruptions of brain net-
works implicated in emotional and cognitive regulation. AAS readily
passes the blood-brain barrier and affect central nervous system func-
tion. AAS binds to cytoplasmic androgen receptors (Janne et al., 1993),
whereby the bound receptor is translocated into the nucleus where it
binds to speciﬁc response elements in target genes and triggers DNA
transcription and protein synthesis (Heinlein and Chang, 2002; Keller
et al., 1996). Androgen receptors are abundantly expressed in the amyg-
dala, hippocampus, brain stem, hypothalamus, and cerebral cortex
(Kritzer, 2004; Pomerantz et al., 1985; Simerly et al., 1990), implicating
a wide range of functions, including regulation of emotion and
cognition.
Commonly, AAS is administrated in cycles lasting for 8–16weeks in-
terspersed with drug-free intervals. During cycles a variety of AAS com-
pounds are usually co-administered known as “stacking” with doses
exceeding therapeutic levels by 5–100-fold inmales [7–9], thereby gen-
erating highly non-physiological levels of endogenous and synthetic
testosterone, with adverse effects on brain function (Clark et al., 1995;
Oberlander and Henderson, 2012). Whereas some users ingest AAS
only a few times during a lifetime, others develop a dependency syn-
drome, with sustained use despite adverse effects (Kanayama et al.,
2009a). The range and severity of the behavioral consequences increasethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ministration suppresses the hypothalamic-pituitary-testicular (HPT)
axis, causing decreased endogenous testosterone production in males
(39, 40). Cycles are used with the rationale that the HPT axis may
recuperate during AAS-free intervals, restoring normal endogenous
testosterone production (Reyes-Fuentes and Veldhuis, 1993). Thus,
classical AAS administration results in substantial ﬂuctuations of
endogenous and synthetic testosterone throughout the cycle. Such
hormonal ﬂuctuations likely inﬂuence brain functions, and might
explain AAS induced alterations in mood and behavior (Pope and
Katz, 1994; Su et al., 1993).
Only one previous study has investigated functional brain networks
as measured using functional MRI (fMRI) after prolonged AAS use.
Using a seed-based approach targeting amygdala connectivity, it was
found that resting-state coupling between the right amygdala and fron-
tal, striatal, limbic, hippocampal, and visual cortical areas, respectively,
was signiﬁcantly lower in 7 users compared to 9 non-users (Kaufman
et al., 2015). Further, a recent meta-analysis of fMRI activation studies
revealed signiﬁcant amygdala foci both after testosterone administra-
tion and in endogenous testosterone studies (Heany et al., 2016), and
higher endogenous testosterone levels have been linked to attenuated
resting-state amygdala-prefrontal coupling in adolescents (Peters et
al., 2015), and in healthy males during a social approach-avoidance
task (Volman et al., 2011), and intranasal testosterone reduced amygda-
la coupling with the orbitofrontal cortex in females (van Wingen et al.,
2011).
Supraphysiological doses of AASmay cause apoptotic effects on a va-
riety of cell types including neurons (Basile et al., 2013; Caraci et al.,
2011; Cunningham et al., 2009; Estrada et al., 2006; Orlando et al.,
2007). In an overlapping sample, prolonged AAS use was associated
with smaller gray matter, cortical and putamen volumes and thinner
cortex, with stronger effects with increasing exposure, also in users
without any other substance abuse (Bjørnebekk et al., 2016). Summa-
rized, converging evidence suggests that prolonged AAS use with
supraphysiological doses is associated with both structural and func-
tional brain alterations. However, available neuroimaging studies of
AAS users are rare and limited by small samples sizes.
The aim of the current study was to test the effects of sustained AAS
use on resting-state functional connectivity in a sample of male long-
termAASusers andnon-users. After rigorous denoising of the individual
datasets to minimize the impact of motion and other artifacts, spatial
maps constituting the nodes in the functional brain network and their
associated time-series were estimated using spatial group independent
component analysis (ICA) and dual regression. We deﬁned the brain
connectivity indices as the between-node partial temporal correlations,
yielding a node-by-node correlation matrix for each dataset, where
each node pair is referred to as an edge in the network. Next, we tested
for associations between AAS status (current user, previous user or con-
trol) and connectivity strength using edgewise analysis. In order to fur-
ther characterize the clinical sensitivity, we tested for associations with
AAS dependency, lifetime exposure and AAS cycle state (on vs. off).
Since elevated testosterone to epitestosterone (T/E) ratio may indicate
use of testosterone, we tested for associations between connectivity
and T/E ratios in the full sample (n = 142).
Based on existing evidence reviewed above, we anticipated that
discriminative connections would implicate regions according to
the anatomical distribution of androgen receptors, including the
amygdala, hippocampus, and brain stem, and their synchronization
with cortical nodes (Kritzer, 2004; Pomerantz et al., 1985; Simerly
et al., 1990). In particular, due to the characteristic emotional conse-
quences of AAS use, and converging neuroimaging evidence
(Kaufman et al., 2015; Peters et al., 2015; van Wingen et al., 2011;
Volman et al., 2011), we expected group differences in amygdala
connectivity and in brain network nodes involved in cognitive and
emotional regulation, which would also be sensitive to the severity
of dependence and total exposure.2. Materials and methods
2.1. Subjects
Table 1 summarizes demographic and clinical characteristics of the
sample. Males engaged in heavy resistance strength training who
were either current or previous AAS users reporting at least one year
of cumulative AAS exposure (summarizing on-cycle periods) or who
had never tried AAS or equivalent doping substances were recruited
through webpages and forums targeting people interested in heavy
weight training, bodybuilding, and online forums (open and closed) di-
rectly addressing steroid use. In addition, posters and ﬂyers were dis-
tributed on select gyms in Oslo. In the recruitment information the
study aim was explicitly stated. Prior to enrollment all participants re-
ceived an information brochure with a complete description of the
study. The studywas approved by the Regional Committees for Medical
andHealth Research Ethics South East Norway (REC) (2013/601), all re-
search was carried out in accordance with the Declaration of Helsinki,
and written informed consent was collected from all subjects. Partici-
pants were compensated with 1000 NOK (approx. 125 USD). The sam-
ple is partly overlapping with the one described in detail in Bjørnebekk
et al. (Bjørnebekk et al., 2016). Here, we were primarily interested in
brain connectivity alterations related to AAS-induced hormonal ﬂuctu-
ations. Thus, for the group analyses participants were divided into cur-
rent, previous or a control group that in addition to self-reports were
conﬁrmed by the doping analyses. Participants failing to meet these
strict group deﬁnitions were excluded from the group analyses, but
were included in analyses testing for associations with T/E ratio across
groups.
Resting-state fMRI data was obtained from 151 individuals, includ-
ing 82 previous or current AAS users and 69 non-users based on self-re-
ports. Of the 69 non-using controls one was excluded due to
neuroradiological ﬁndings, one because he failed to match criteria for
strength training (see Bjørnebekk et al., 2016 for details). In addition,
three participants were excluded due to missing urine samples and
ﬁve for having T/E ratios N 4 (range 4.3–8.4), which might indicate ad-
ministration of testosterone, yielding 59 participants in this group.
Among the 82 AAS users with rFMRI data, two subjects were excluded
due to less than a year of accumulated use, and two due to missing
urine sample. The remaining 78 datasets comprised 58 current users
and 20 previous users. Among the 58 current users reporting AAS use
within the past 12 months eight were excluded due to a negative AAS
test, yielding 50 current users. Among the 20 previous users with a
self-reported history of AAS use in the past (N12 months prior to scan-
ning) fourwere excluded due to traces of AAS or testosterone use in the
urine, yielding 16 previous users. Supplemental Table 1 provides group
summary stats and comparison on use characteristics for current, previ-
ous and excluded users. Material and methods used to assess AAS use,
medical history, AAS dependence, verbal IQ, alcohol and drug use,
mood and problem behavior are summarized in the Supplement.
2.2. Doping analysis
Urine samples were collected at the same visit as the cognitive test-
ing and analyzed for AAS and narcotics by gas chromatography and
mass spectrometry at theWADA accredited Norwegian Doping Labora-
tory at Oslo University Hospital (Hullstein et al., 2015). Stimulants were
analyzed by liquid chromatography and mass spectrometry.
Brieﬂy, the criteria used to determine the use of AAS or testosterone
are 1) urine samples positive for AAS compounds 2) a T/E ratio N 4 as has
been applied by World Anti-Doping Agency as a population based
criteria for samples requiring further analysis by isotope ratio mass
spectrometry (IRMS) or follow up to indicate testosterone abuse
(group, 2016). When applying this criterion in research and routine
analyses, cases of naturally occurring T/E ratios above 4 appear
(Mareck et al., 2010), and sometimes a stricter T/E ratio is preferred
Table 1
Group comparisons on main attributes; demographic information, training information, drug and psychopharmaca use, emotional and behavioral problems.
Controls (n = 59) Current AAS users
(n = 50)
Previous AAS users
(n = 16)
M SD M SD M SD F p
Age (years) 30.7 7.4 33.6 8.7 31.7 5.2 1.967 0.144
Education (years) 15.9 2.7 14.5 2.6 14.2 1.9 5.230 0.007 a⁎
IQ 112.7 9.5 105.9 12.6 107.3 10.1 5.518 0.005 a⁎⁎
Height 180.7 6.5 181.1 6.9 180.5 6.9 0.084 0.920
Weight 90.2 14.5 99.1 12.0 93.9 15.4 5.737 0.004 a⁎⁎
BMI 27.6 4.0 30.2 3.6 28.7 4.0 6.243 0.003 a⁎⁎
Strength training/week (min) 477.3 247.4 383.7 217.4 223.3 123.2 8.600 b0.001 b⁎⁎⁎, c⁎
Endurance training/week (min) 92.9 118.4 115.8 197.1 78.1 106.1 0.481 0.619
Cigarettes (day) 0.4 2.6 1.8 4.3 0.6 2.3 2.631 0.076
Alcohol units (week) 3.5 5.1 1.6 3.2 1.4 2.3 3.600 0.030 a⁎
Psychopharmaca (previous or current use) n % n % n %
Antidepressants 2 3.4 10 20.0 3 18.8
Anxiolytics 0 0.0 7 14.0 2 12.5
Opioids 0 0.0 2 4.0 0 0.0
More than one sort 0 0.0 3 6.0 0 0.0
None reported 55 93.2 37 74.0 11 68.8
Emotional and problem behavior
Anxious/depressed 52.2 4.3 54.5 6.7 58.6 9.0 6.300 0.003 b⁎⁎
Rule breaking behavior 52.5 5.1 59.3 11.0 58.9 7.9 9.197 b0.001 a⁎⁎⁎, b⁎
Internalizing problems 45.9 9.9 51.3 11.0 56.3 13.3 5.958 0.004 a⁎, b⁎⁎
Externalizing problems 46.4 8.4 55.0 8.8 55.7 11.1 13.172 b0.001 a⁎⁎⁎,b⁎⁎
Total problems 21.1 15.6 33.8 21.2 42.8 25.5 8.752 b0.001 a⁎⁎, b⁎⁎
Tobacco 55.9 5.3 54.1 4.9 55.8 5.6 1.501 0.228
Alcohol 60.1 7.0 56.8 6.8 59.5 8.5 2.637 0.076
Drugs 51.4 7.0 57.5 12.9 56.6 9.8 4.564 0.013 a⁎⁎
Bonferroni Post Hoc test a = control signiﬁcantly different from current users, b = controls signiﬁcantly different from previous users, c = current AAS users signiﬁcantly different from
previous AAS users.
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001.
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provides a summary of the frequency of the speciﬁc anabolic-androgen-
ic steroids found in theurine sample, and Supplemental Table 3 summa-
rizes the most popular compounds based on self-reports.
2.3. MRI acquisition
MRI scans were obtained on a Siemens Skyra 3T scanner with a 24-
channel head coil at Oslo University Hospital. We acquired structural
MRI with a T1-weighted 3D magnetization-prepared rapid gradient-
echo (MPRAGE) sequence, with the following parameters (TR:
2300 ms; TE: 2.98 ms; FA: 8°; voxel size: 1 × 1 × 1 mm; 176 sagittal
slices) and fMRI data with a T2*-weighted 2D gradient echo-planar im-
aging sequence (EPI) with 150 volumes (TR: 2390 ms; TE: 30 ms; FA:
90°; voxel size: 3 × 3 × 3 mm; 43 axial slices). Participants were
instructed to keep their eyes open.
2.4. MRI processing and network estimation
For fMRI analysis we used the FMRI Expert Analysis Tool (FEAT)
from the FMRIB Software Library (FSL) (Smith et al., 2004). The pipeline
included motion correction (MCFLIRT), spatial smoothing (full width at
halfmaximumof 6mm), grand-mean intensity normalisation of the en-
tire 4D dataset by a single multiplicative factor, high-pass temporal ﬁl-
tering (Gaussian-weighted least-squares straight line ﬁtting, sigma =
45 s), and single-session independent component analysis (ICA) using
MELODIC (Beckmann and Smith, 2004)
We used FIX (ICA-based Xnoiseﬁer (Salimi-Khorshidi et al., 2014)),
to identify and remove noise components on an individual level using
a machine learning approach with a standard training set (threshold:
20). FIX was recently shown to outperform several different methods
for data cleaning (Pruim et al., 2015)). Supplemental Fig. 2 shows aver-
age temporal signal-to-noise ratio (tSNR) (Roalf et al., 2016) before andafter FIX, and details regarding group differences are reported in the
Supplement.
We extracted brain masks from the T1-weighted volumes using
Freesurfer (Fischl et al., 2002), used for registration to standard space
using FLIRT (Jenkinson and Smith, 2001)with boundary-based registra-
tion (BBR, (Greve and Fischl, 2009)) and FNIRT (Andersson et al., 2010).
After registration, we employed group independent component
analysis using MELODIC including all datasets by mean of a group-PCA
technique (Smith et al., 2014). Automated model order selection
yielded 47 components. Next, for each subject we estimated individual
time series and component spatialmaps using dual regression (Filippini
et al., 2009). Per recommendations (Kelly et al., 2010), based on the
component spatial maps and the frequency spectrum of the time series,
we identiﬁed six noise components and regressed the time-series from
these out of the remaining components. Next, we excluded another 11
components ofwhich spatialmapswere not corresponding to any inter-
pretable neuronal origin or were outside the mask. The remaining 30
components constituted the nodes in subsequent network analyses,
and the corresponding 435 temporal partial correlations between each
component pairs formed the edges (connections) of the full network.
As in previous studies (Kaufmann et al., 2016; Kaufmann et al., 2015;
Skatun et al., in press), for each subject, we computed the regularized
partial correlations (Smith et al., 2011) with automated individual esti-
mation of regularization strength (Ledoit and Wolf, 2003).
2.5. Statistical analysis
We assessed effects of AAS use on between-node connectivity by
comparing current users, previous users and controls using analysis of
covariance (ANCOVA) on each network edge, covarying for age. We
corrected for multiple comparisons using Bonferroni correction across
all 435 edges (adjusted alpha = 0.05/435). Next, in any edges showing
signiﬁcant effects of group, we tested for associationswith dependency,
life time exposure, and cycle state using ANCOVAs covarying for age
65L.T. Westlye et al. / NeuroImage: Clinical 13 (2017) 62–69(see Supplemental Information for details). To assess the relative im-
portance of each node in distinguishing between groups, we calculated
the eigenvector centrality of each node based on the edge-wise F-values
from the groupANCOVA. A high centrality indicates altered connectivity
with several other nodes, indicating a relative importance of this node
in discriminating between groups, regardless of the signiﬁcance thresh-
old applied on the edge level.
To control for the possible inﬂuence of general cognitive function,
aspects of mental health, alcohol and drug use on between-node con-
nectivity, we conducted additional analyses where IQ, weekly alcohol
consumption and the ASEBA ASR T-scores for anxious/depressed syn-
drome, drug use, attention problem and total problems were included
as additional covariates (one at a time). Also, we conducted analyses
where participants with traces of narcotics in the urine were excluded,
in order to reassure that the ﬁndings were not a result of the use of nar-
cotics. Finally, we assessed the relations between T/E ratio and edge
strengths by Spearman's Rho correlations (T/E ratio distribution was
positively skewed) across the full sample (n = 142).
3. Results
3.1. Edgewise connectivity
Fig. 1A shows the results from the edgewise ANCOVA testing for dif-
ferences between current AAS users (n= 50), previous AAS users (n=
16) and controls (n = 59). 49 (11.3%) of the edges showed nominal
(p b 0.05, uncorrected) and two edges showed signiﬁcant (p b 0.05,
Bonferroni corrected) group effects. The two signiﬁcant edges com-
prised the connections between the default mode network (DMN)
and the amygdala (F=10.2, p b 8e−05), and between the dorsal atten-
tion network (DAN) and a node encompassing the superior and inferior
frontal gyrus (SFG/IFG) and the anterior portions of the anterior cingu-
late cortex (ACC) (F 9.8, p b 1e−04), both indicating reductions in func-
tional connectivity in current AAS users compared to both non-users
(t N 4.0, p b .1e−04) and previous users (t N 2.1, p b 0.03), yet no differ-
ence between previous users and controls (t b 0.97, p N 0.33). Fig. 1B–C
illustrates the corresponding connectivity patterns for both edges. The
ﬁndings were replicated in analyses excluding participants with traces
of narcotics in the urine, or with concurrent substance abuse. IncludingFig. 1. Results from the edgewise ANCOVA testing for differences between current AAS users, p
and two edges showed signiﬁcant (p b 0.05, Bonferroni corrected) group effects, indicating red
SFG/IFG/ACC. Fig. 1B–C shows the mean connectivity within each of the groups for the two sigIQ, drug use, alcohol consumption, symptoms of anxiety and depression,
attention problems and ASR total problem scores in the statistical
models onlymarginally inﬂuenced the ﬁndings (Supplemental Table 4).
Supplemental Fig. 3 shows the EC value per node, reﬂecting a
nodewise summary measure of effect size on tests for differences
between current users, previous users and controls. The nodes
showing strongest overall centrality were IC22 (SFG/IFG/ACC) and
IC16 (DAN).
Fig. 2A splits current AAS users into individuals with (n = 27) and
without (n= 23) dependence.Whereas the difference between depen-
dent and non-dependent userswas not signiﬁcant in the DMN-amygda-
la edge, there was a clear pattern of controls N non-dependent users N
dependent users in the DAN-SFG edge, with dependent users signiﬁ-
cantly different both from non-dependents users (t = 2.6, p = 0.01)
and controls (t = 5.1, p = 2e−06).
Fig. 2B splits the current AAS users according to their lifetime expo-
sure (low dose: n=15,mediumdose: n=17, high dose: n=17). Both
edges revealed a clear dose effect. There was a nominal signiﬁcant dif-
ference between low dose and medium dose in the DMN-amygdala
edge (t = 2.7, p = 0.013) and close to signiﬁcance for low vs. high
dose (t=2.0, p=0.054). Controlswere signiﬁcantly different fromme-
dium and high dose lifetime exposure groups. The DAN-SFG edge re-
vealed a striking connectivity pattern of low dose N medium
dose N high dose, although only differences between controls and any
of the dose groups were signiﬁcant.
Fig. 2C splits current users into those currently off cycle (n=15) and
those currently on cycle (n = 29), revealing a pattern of off cycle N on
cycle in mean connectivity. For the DMN-amygdala edge, controls sig-
niﬁcantly differed from current users on cycle (t = 4.0, p = 1e−04)
but not off cycle (t= 1.5, p= 0.13). For the DAN-SGF edge, controls dif-
fered from users on (t = 4.6, p = 1e−05) and off cycle (t = 2.9, p =
0.005).
Finally, we assessed associations between T/E ratio and connec-
tivity in the two main edges across the full sample (n = 142),
independent of group assignment. Fig. 3A–B reveals decreased con-
nectivity with increasing T/E, both for DMN-amygdala
(rho = −0.24, p = 4e−03) and DAN-SFG (rho = −0.32, p =
1e−04). Supplemental Fig. 4 illustrates that the negative association
persists across the full T/E span.revious AAS users and controls. Fig. 1A: 49 edges showed nominal (p b 0.05, uncorrected)
uced connectivity in links between the DMN and the amygdala, and between the DAN and
niﬁcant edges. Error bars denote standard error of the means (SEM).
Fig. 2. Edge connectivity stratiﬁed by clinical information. Fig. 2A:Mean connectivity for current AAS userswith andwithout dependence. Fig. 2B:Mean connectivity for current AAS users
by lifetime exposure (low dose,medium dose, high dose). Fig. 2C: Mean connectivity strength for current AAS users by cycle status (on/off). Error bars denote standard errors of themean
(SEM).
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In addition to denoising individual fMRI datasets using FIX (Salimi-
Khorshidi et al., 2014), we tested if effects of AAS remained when in-
cluding tSNR and motion as additional covariates in the statistical
models. Brieﬂy, whereas effect sizes were somewhat reduced, both
edges still showed signiﬁcant group effects (DMN-amygdala: F = 6.8,
p = 0.002, DAN-SFG: 6.6, p = 0.001) when accounting for tSNR and
motion.4. Discussion
In the largest functional neuroimaging study of current and previous
AAS users to date, we have demonstrated robust functional brain con-
nectivity reductions between major brain hubs modulating emotional
and cognitive functions. Speciﬁcally, we have documented reduced con-
nectivity between the DMN and the amygdala and between the DAN
and a frontal node encompassing the SFG, IFG and the ACC in current
users compared to non-users and previous users. The connectivity was
further reduced in dependent users or those on cycle, showed a graded
pattern of reductions when comparing subjects with low, medium and
high lifespan exposure, and was negatively correlated with T/E ratio
across the full sample.
Both theoretical considerations and empirical evidence suggest in-
volvement of the amygdala as a hub mediating the adverse behavioral
and emotional effects of AAS. However, sample sizes have been limited,
which challenges the reliability of previous reports. Therefore, we ap-
plied a data driven approach, allowing detection of additional hubs be-
yond the amygdala, and assessment of anatomical speciﬁcity. In lineFig. 3. Edge connectivity plotted as a function ofwith our hypotheses, we observed amygdala connectivity reduction in
users, and further reductions with increased lifetime use and T/E ratio.
Despite the use of methods that are not necessarily directly compa-
rable, our data-driven approach supports evidence from a small-scale
study suggesting decreased functional connectivity between the amyg-
dala and other brain regions in AAS users versus non-users (Kaufman et
al., 2015). The ﬁndings are also in accordance with previous fMRI re-
ports linking increases in testosterone levels to reductions in amygda-
la-prefrontal coupling (Peters et al., 2015; Spielberg et al., 2015;
Volman et al., 2011), and reinforces the notion that testosterone ﬂuctu-
ations affect networks in the brain which are critically involved in emo-
tional processing and regulation (Li et al., 2014; Phelps and LeDoux,
2005).
TheAAS effects on amygdala coupling are compatiblewith amygdala
being among the brain regions with the highest androgen receptor
mRNA density (Menard and Harlan, 1993; Michael et al., 1995;
Simerly et al., 1990). AAS has been associated with a wide array of ad-
verse effects on mental health and also cognitive deﬁcits (Heffernan et
al., 2015b; Kanayama et al., 2012; Kaufman et al., 2015; Su et al.,
1993). Perturbations of amygdala connectivity with cognitive and emo-
tional network hubs including the DMN could potentially constitute
brain correlates of these side effects.
In an overlapping sample it was recently reported smaller neuroan-
atomical volumes in AAS-users compared to non-users, including over-
all cortical, total gray matter, corpus callosum and putamen volumes
and thinner cortex inwidespread regions, including the posterior cingu-
late cortices, which are key regions in the DMN (Bjørnebekk et al.,
2016). Whereas DMN connectivity has been implicated in a range of
psychiatric and neurological conditions (Buckner et al., 2008;
Whitﬁeld-Gabrieli and Ford, 2012), suggesting that DMN connectivityT/E ratio across the full sample (n = 142).
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duced DMN-amygdala connectivity are in line with extant evidence of
emotional dysregulation in AAS users.
The other edge showing reduced connectivity in AAS users implicat-
ed the DAN and the SFG/IFG/ACC. DAN, comprising key hubs in the
intraparietal sulcus (IPS), superior parietal lobule (SPL), and the frontal
eye ﬁeld (Corbetta et al., 2008), constitutes a core attention node. The
connectivity patterns of the DAN are predictive of cognitive load during
a multiple object tracking (Alnaes et al., 2015), which supports its sen-
sitivity to mental states associated with goal-driven attention. SFG con-
stitutes a collection of distinct subregions in the prefrontal cortex,which
has been implicated in a wide range of executive functions, including
working memory and cognitive control (du Boisgueheneuc et al.,
2006; Fuster, 2001). The structural connectivity patterns of the
anteromedial part of the SFG, which showed strongest loading in the
implicated component, have been involved in response selection and
cognitive and attentional control (Li et al., 2013). The right IFG has con-
sistently been implicated in response inhibition and impulse control
(Aron et al., 2014), and damage of the right IFG are detrimental for
stop-signal inhibition (Aron et al., 2003). Strikingly, activation of the
right IFGwas related to the speed of the inhibition process and use of il-
legal substances in a large sample of adolescents (Whelan et al., 2012),
and a single administration of testosterone altered the connectivity be-
tween the IFG and the ACC in healthy females (Bos et al., 2016). Al-
though not representing a speciﬁc involvement (Wager et al., 2016),
the critical role of the dorsal ACC in cognitive, motor and attentional
control is well established (Bush et al., 2000), and along with implica-
tions of the dorsal ACC for reward-based decision-making (Bush et al.,
2002), reduced connectivity with the DANmay reﬂect impaired coordi-
nated neuronal processing related to cognitive control and impulsivity
in AAS users. Our current ﬁndings are in line with a previous magnetic
resonance spectroscopy (MRS) study reporting neurochemical abnor-
malities in the dorsal ACC in AAS users, likely reﬂecting increased gluta-
mate turnover (Kaufman et al., 2015).
In contrast to the DMN-amygdala connection, the SFG/IFG/ACC-DAN
edgewas lower also in previous users compared to controls, and further
reductions with increased dependency and lifetime exposure suggest
an association with sustained use. This ﬁts with the observation of re-
duced cognitive function after long-term use. Although further studies
are needed to establish the reliability and state-dependency of these
ﬁndings, they may suggest a chronic state conferring risk of long-term
use and cognitive impairment.
In line with the state-dependency of functional imaging indices, the
effects seems to be partly driven by current use, underscored by corre-
lations between connectivity in both edges and T/E ratio, and the lack
of differences between non-users and previous users on the amygda-
la-DMN edge. This could reﬂect the transient and state-dependent na-
ture of resting state patterns, partly mediated by hormonal
ﬂuctuations. Typical AAS administration regiments results in highly
non-physiological levels of androgens and their metabolites, and large
ﬂuctuations at different time points in the cycle. Hormonal ﬂuctuations
of this kind are likely to inﬂuence brain functions, and might explain
AAS induced alterations in mood and behavior (Pope and Katz, 1994;
Su et al., 1993).
This study does not come without limitation. First, the study design
does not allow for claims regarding causality. In linewithmost observa-
tional and correlational studies, it is conceivable that predisposed vari-
ables conferring risk for AAS use (personality etc) may reﬂect
confounding factors. Effects of such inherent associations should ideally
be handled by design, e.g. by a prospective and randomized experimen-
tal study. Further, whereas the results suggest the involvement of selec-
tive large-scale brain functional networks, the neurobiological
speciﬁcity of fMRI-based data is limited, which complicates a direct
mechanistic interpretation. Indeed, the actions of AAS are complex
and multifactorial, including both the described genomic effects but
also additional non-genomic actions, estrogen receptor binding, andsecondary modulatory effects on the hypothalamic-pituitary-adrenal
(HPA) axis and inﬂuence of classical neurotransmitter and neuropep-
tide signaling. Further, the diversity of AAS effects on behavior reﬂects
interactions between many factors, including predisposing vulnerabili-
ty, age, sex, type(s) of AAS used, doses and method of administration
(Oberlander and Henderson, 2012). Although the observed correlations
with T/E ratio suggest an acute effect of AAS, the associations with de-
pendency and life time exposure also indicate a cumulative effect of
sustained use. Further studies are needed to disentangle the acute and
chronic inﬂuences of AAS use on brain and cognitive function, which
is critical for informing predictive and prognostic models of the long-
term impact of AAS use. In line with the reported sex differences in
AAS use (Kanayama et al., 2007; Pope et al., 2014), we included male
subjects only. Further studies are needed to address the generalizability
to the female population. Lastly, the consequences of AAS use are not
conﬁned to the brain. In particular, cardiovascular conditions, including
hypertension, atherosclerosis and dyslipidemia, are substantial risks as-
sociated with AAS use (Vanberg and Atar, 2010). These cardiovascular
risk factors could also inﬂuence the fMRI signal, which is modulated
by complex neurovascular interactions (Logothetis, 2008), and future
studies may be able to directly assess the common and unique effects
on the brain and the cardiovascular system.
In conclusion, in the largest sample to date we have demonstrated
reduced resting-state functional connectivity between brain network
nodes critically involved in cognitive and emotional regulation, includ-
ing the amygdala, the DMN, the DAN and SFG/IFG/ACC in AAS users.
The brain connectivity ﬁndings are in linewith the characteristic neuro-
psychiatric and cognitive consequences of sustained AAS use, including
emotional and behavioral dysregulation. Associations with T/E ratio
support sensitivity to current hormonal levels, and connectivity reduc-
tions with increased life time exposure and dependency suggest cumu-
lative effects of sustained AAS use.
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